Welcome to our dedicated page for Staar Surg news (Ticker: STAA), a resource for investors and traders seeking the latest updates and insights on Staar Surg stock.
Staar Surgical Co (NASDAQ: STAA) is a prominent player in the ophthalmic surgery market, with over three decades of experience. The company specializes in the development, manufacture, and marketing of implantable lenses and accompanying delivery systems for the eye. Staar Surgical's flagship product line includes the EVO Visian Implantable Collamer® Lenses (ICLs), which are used to treat a variety of visual disorders such as myopia, hyperopia, astigmatism, and presbyopia.
These lenses are designed to provide visual freedom to patients, significantly reducing or eliminating their reliance on glasses or contact lenses. The EVO Visian ICLs are foldable, allowing for a minimally invasive procedure where the lens is inserted through a small incision. This innovative approach not only enhances surgical outcomes but also minimizes recovery time for patients.
To date, nearly 600,000 EVO Visian ICLs have been implanted worldwide, showcasing the trust and effectiveness of Staar Surgical's products. Additionally, the company offers minimally invasive intraocular lenses (IOLs) geared towards cataract surgery. These include foldable IOLs and aspheric IOLs that deliver a clearer image compared to traditional spherical lenses.
Staar Surgical's commitment to advancing ophthalmic technology is evident in its continuous efforts to improve product offerings and expand its market reach. The company has formed strategic partnerships and collaborations to bolster its research and development initiatives, ensuring the delivery of cutting-edge solutions in eye care.
Financially, Staar Surgical has shown consistent growth, with the majority of its revenue generated from the ophthalmic surgical product segment. The company's focus remains on innovation and quality, driving its mission to enhance vision care globally.
STAAR Surgical Company (NASDAQ: STAA), a leading developer of the EVO family of Implantable Collamer® Lenses (EVO ICL™), has announced its plans to release second quarter 2024 financial results on August 7, 2024, after market close. The company will host an earnings webcast at 4:15 p.m. ET / 1:15 p.m. PT on the same day to discuss financial results and operational progress. Investors can access the webcast through the company's website or a dedicated link. STAAR Surgical has been focused on ophthalmic surgery for over 40 years and has sold more than 3,000,000 ICLs in over 75 countries. The company operates manufacturing facilities in California and Switzerland.
STAAR Surgical Company (NASDAQ: STAA), a leading developer of the EVO family of Implantable Collamer® Lenses, announces its participation in the Canaccord Genuity 44th Annual Growth Conference in Boston. Patrick F. Williams, Chief Financial Officer, will engage in a fireside chat on August 13, 2024, at 8:30 a.m. Eastern Time. Investors and the public can access a live webcast of the event through STAAR's investor website.
STAAR Surgical, with over 40 years of focus on ophthalmic surgery, specializes in implantable lenses for visual freedom. Their EVO ICL™ product line has sold more than 3,000,000 ICLs globally, marketed in over 75 countries. The company operates facilities in California and Switzerland, continuing its commitment to innovative eye care solutions.
STAAR Surgical Company (NASDAQ: STAA), a leader in developing and marketing Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism, and presbyopia, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference.
Chief Financial Officer Patrick F. Williams will represent STAAR in a fireside chat on June 12, 2024, at 8:00 a.m. Eastern Time. The event will be webcast live, with a recording available on STAAR's investor website afterward.
STAAR has been dedicated to ophthalmic surgery for over 40 years, selling over 3 million ICLs in more than 75 countries. Headquartered in Lake Forest, CA, the company operates production facilities in the U.S. and Switzerland.
STAAR Surgical Company reported a 5% increase in net sales to $77.4 million for the first quarter of 2024. The company saw a 9% growth in ICL sales and a 2% increase in units. Gross margin was at 78.9%, and adjusted EBITDA was $5.3 million or $0.11 per share. However, there was a net loss of $3.3 million or $0.07 loss per share compared to net income of $2.7 million or $0.05 income per share in the previous year. STAAR Surgical reiterated its fiscal 2024 net sales outlook range of $335 million to $340 million and expects to be at the higher end of the range. Cash, cash equivalents, and investments available for sale were $252.1 million at the end of March 29, 2024.
STAAR Surgical Company (NASDAQ: STAA) has announced a strategic agreement with IQ Laser Vision, making EVO ICL lenses a primary option for patients seeking surgical vision correction in the U.S. This partnership aims to significantly increase the availability of EVO ICL lenses to qualified patients across IQ Laser Vision's practices.
STAAR Surgical Company (NASDAQ: STAA) announced the appointment of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel to drive innovation and growth. Nancy brings extensive experience from Johnson & Johnson, while Nate joins from NuVasive. This move reflects the company's commitment to enhancing brand awareness and legal functions globally. The new executives will play a vital role in accelerating growth and expanding the market for the EVO family of Implantable Collamer Lenses.
STAAR Surgical Company (NASDAQ: STAA) will report financial results for the first quarter ended March 29, 2024, on May 7, 2024. The company will host a conference call and webcast to discuss its performance. STAAR is a leading developer, manufacturer, and marketer of Implantable Collamer® Lenses for myopia, astigmatism, and presbyopia, with over 40 years of experience in ophthalmic surgery. The company's lenses provide visual freedom for patients, reducing the need for glasses or contact lenses. STAAR operates manufacturing facilities in the US and Switzerland and markets its products in over 75 countries.
FAQ
What is the current stock price of Staar Surg (STAA)?
What is the market cap of Staar Surg (STAA)?
What does Staar Surgical Co specialize in?
What are EVO Visian Implantable Collamer Lenses (ICLs)?
How many EVO Visian ICLs have been implanted to date?
What are the main types of products offered by Staar Surgical Co?
What are the benefits of Staar Surgical's foldable lenses?
What financial segment contributes most to Staar Surgical's revenue?
What innovations have Staar Surgical introduced in cataract surgery?
How does Staar Surgical ensure the quality of its products?
What are the core markets for Staar Surgical's products?
What are some recent achievements of Staar Surgical?
